Galena Is Stirring Traders' Passions

 | Jan 17, 2014 | 11:07 AM EST  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

gale

There are a lot of GALEs out there right now. I'm talking about Galena Biopharma (GALE), a biotech that's gone from $2 to $7 and change in a very short time. Galena has a potential vaccine for some forms of breast cancer, among other drugs, and it has become the latest stock to be bid up on hope and on tests that may or may not conclusively show whether the vaccine works.

Gale has a lot of boosters, including people who write on websites without disclosing their names. The stories are very compelling. They make you want to buy it. Adam Feuerstein, who writes for us, has been as critical as you can be about the company, so when someone called about it and I said it seemed to be an interesting spec -- which it most surely is -- the stock jumped another 18%.

So I said I wanted to learn more, and the company's CEO, Mark J. Ahn, came on the show.

After asking about a big partnership with Dr. Reddy, the huge Indian pharma concern, I asked about Adam's issues and about a University of Pennsylvania study that questions the efficacy of vaccines like the one for which Galena is trying to win approval.

No sooner did I do that than the supporters of Galena turned on me. I had broken the cheering chorus by asking tough questions.

Immediately, I was hailed as someone owned by the shorts or who wanted to break Galena's stock. I had to laugh at that. I have been a reporter for 38 years. The goal of a reporter is to try to be skeptical. I did my job.

More important, though, you can see how people are desperate right now for momentum stocks to go higher. This group would have loved me if I said, "Buy GALE." But that wasn't my job. My job was to find out more.

I did

Now it is up to people to make up their own minds. But I am worried that here is another cult stock. It's one where the science better be right or it is going right back where it came from.

And maybe it is right. We just don't know yet. But we do know there are a pro and a con, and that's what matters, not just the pro.

Columnist Conversations

At the bottom last Wednesday I doubt that many people would have predicted the headline above. I certainly wo...
FB has earnings due out on 10-28-2014, after the market closes. I will write a full earnings preview for Mark...
Solid opening day to trading week for a change as indices across the board as even the DJIA manages to end up ...
Apple reports after the close today. St expecting Q4 rev of $39.877 billion, up 6.4%. EPS of $1.31. FY14 rev o...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.